Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVpreF and HZ/su vaccine coadministration in adults ≥50 years
NCT06890416Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2025
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, open-label trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Pfizer. Primary endpoints: Geometric Mean Ratio of Neutralizing Titers for RSV A and B, Geometric Mean Concentration of anti-gE antibodies and 4 more. Started Apr 2025; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06890416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890416.